ERBB2 and breast cancer: BC is not one single disease, but rather a group of intrinsically distinct disease entities or subtypes, such as Luminal A, Luminal B, HER-2 enriched and basal-like (triple negative), which are molecularly heterogeneous and exhibit different prognoses and responses to therapy [3].